Evidence map›Paper›PMID 42189455›Full record

ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2026

Catheter ablation of atrial fibrillation in patients with heart failure - preserved and reduced ejection fraction - real world evidence.

Maximilian Moersdorf, Qussay Marashly, Christian Massad, Yara Menassa, Han Feng, Michel Abou-Khalil, Mohammad Montaser Atasi, Alex El Darzi, Carlo El Khoury, Philipp Sommer and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maximilian MoersdorfTulane Research Innovation for Arrhythmia Discovery, New Orleans, LA, USA.
Qussay MarashlyTulane Research Innovation for Arrhythmia Discovery, New Orleans, LA, USA.
Christian MassadTulane Research Innovation for Arrhythmia Discovery, New Orleans, LA, USA.
Yara MenassaTulane Research Innovation for Arrhythmia Discovery, New Orleans, LA, USA.
Han FengTulane Research Innovation for Arrhythmia Discovery, New Orleans, LA, USA.
Michel Abou-KhalilTulane Research Innovation for Arrhythmia Discovery, New Orleans, LA, USA.
Mohammad Montaser AtasiTulane Research Innovation for Arrhythmia Discovery, New Orleans, LA, USA.
Alex El DarziTulane Research Innovation for Arrhythmia Discovery, New Orleans, LA, USA.
Carlo El KhouryTulane Research Innovation for Arrhythmia Discovery, New Orleans, LA, USA.
Philipp SommerDepartment of Electrophysiology, Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany.
Amitabh C PandeyTulane Research Innovation for Arrhythmia Discovery, New Orleans, LA, USA.
Christian SohnsDepartment of Electrophysiology, Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany.
Nassir MarroucheTulane Research Innovation for Arrhythmia Discovery, New Orleans, LA, USA. nmarrouche@tulane.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCatheter ablation for atrial fibrillation (AF) has been shown to reduce mortality and morbidity in patients with AF and heart failure with reduced ejection fraction (HFrEF) compared with medical therapy (GDMT) alone. Outcomes in patients with preserved ejection fraction remain less clearly defined. This study compared long-term outcomes of catheter ablation in patients with AF and heart failure (HF) across the spectrum of ejection fraction using real-world data.

methodsThis retrospective cohort study utilized the U.S. Collaborative Network in TriNetX to identify adults with AF and HF between September 2018 and September 2024. After 1:1 propensity score matching, 12,492 patients with HFpEF and AF and 38,150 patients with HFrEF were included. The primary endpoint was a composite including all-cause mortality, left-ventricular-assist device implantation, or heart transplantation. Secondary endpoints included hospitalization, stroke, and antiarrhythmic drug (AAD) use. Outcomes were compared between patients receiving ablation and GDMT versus GDMT alone.

resultsOver a mean follow-up of 973 days (HFpEF) and 926 days (HFrEF), AF ablation was associated with lower risks of the primary endpoint and mortality (HFpEF: hazard ratio (HR) 0.29; HFrEF: HR 0.40; all p < 0.001), as well as reduced hospitalization (HFpEF: HR 0.81; HFrEF: HR 0.75; all p < 0.001) and stroke (HFpEF: HR 0.86, p = 0.025; HFrEF: HR 0.76, p < 0.001). Patients that received ablation had more frequent AAD use despite greater cardioversion rates (HFpEF: HR 1.37; HFrEF: HR 1.08, all p < 0.001).

conclusionCatheter ablation conferred comparable reductions in mortality, advanced HF therapies, stroke, and hospitalization in both HFpEF and HFrEF patients.

Indexed as

All-cause mortalityAtrial fibrillationCatheter ablationHeart failureHFpEFHFrEF

Identifiers

PMID42189455

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.